Literature DB >> 26208947

Come together, right now….

Herman Yeger1.   

Abstract

Editing the genome using approaches like TALEN and siRNA are already well tested. The new kid on the block is CRISPR-Cas9. CRISPR-Cas9 is rapidly evolving with impressive refinements for specificity, eliminating off-target effects, and versatility. One can adjust constructs and conditions to produce opposite effects on the genome and for a specific purpose. The nuances of the system, the means to significantly reduce off-targeting, and numerous applications are now emerging rapidly. This B&B commentary looks forward into how the CRISPR-Cas9 tool might serve the CCN field.

Keywords:  CCN applications; CRISPR-Cas9; Correcting human disease; Genome editing

Year:  2015        PMID: 26208947      PMCID: PMC4580680          DOI: 10.1007/s12079-015-0301-y

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  22 in total

Review 1.  Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR.

Authors:  Michael Boettcher; Michael T McManus
Journal:  Mol Cell       Date:  2015-05-21       Impact factor: 17.970

2.  Nov/CCN3 regulates long-term repopulating activity of murine hematopoietic stem cells via integrin αvβ3.

Authors:  Jun Ishihara; Terumasa Umemoto; Masayuki Yamato; Yoshiko Shiratsuchi; Satoshi Takaki; Brian G Petrich; Hiromitsu Nakauchi; Koji Eto; Toshio Kitamura; Teruo Okano
Journal:  Int J Hematol       Date:  2014-02-22       Impact factor: 2.490

Review 3.  Expanding the Biologist's Toolkit with CRISPR-Cas9.

Authors:  Samuel H Sternberg; Jennifer A Doudna
Journal:  Mol Cell       Date:  2015-05-21       Impact factor: 17.970

Review 4.  The impact of CRISPR-Cas9 on target identification and validation.

Authors:  Jonathan D Moore
Journal:  Drug Discov Today       Date:  2015-01-05       Impact factor: 7.851

Review 5.  Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer.

Authors:  Julia E Wells; Meegan Howlett; Catherine H Cole; Ursula R Kees
Journal:  Int J Cancer       Date:  2014-05-30       Impact factor: 7.396

Review 6.  Concise Review: Cardiac Disease Modeling Using Induced Pluripotent Stem Cells.

Authors:  Chunbo Yang; Jumana Al-Aama; Miodrag Stojkovic; Bernard Keavney; Andrew Trafford; Majlinda Lako; Lyle Armstrong
Journal:  Stem Cells       Date:  2015-06-23       Impact factor: 6.277

7.  Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.

Authors:  David G Ousterout; Ami M Kabadi; Pratiksha I Thakore; William H Majoros; Timothy E Reddy; Charles A Gersbach
Journal:  Nat Commun       Date:  2015-02-18       Impact factor: 14.919

Review 8.  Revisiting the matricellular concept.

Authors:  Joanne E Murphy-Ullrich; E Helene Sage
Journal:  Matrix Biol       Date:  2014-07-24       Impact factor: 11.583

Review 9.  A CRISPR view of development.

Authors:  Melissa M Harrison; Brian V Jenkins; Kate M O'Connor-Giles; Jill Wildonger
Journal:  Genes Dev       Date:  2014-09-01       Impact factor: 11.361

Review 10.  New strategy to control cell migration and metastasis regulated by CCN2/CTGF.

Authors:  Diego Pinheiro Aguiar; Gabriel Correa de Farias; Eduardo Branco de Sousa; Juliana de Mattos Coelho-Aguiar; Julie Calixto Lobo; Priscila Ladeira Casado; Maria Eugênia Leite Duarte; José Garcia Ribeiro Abreu
Journal:  Cancer Cell Int       Date:  2014-07-12       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.